Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 1034Neoplasms 815Carcinoma, Non-Small-Cell Lung 799Prostatic Neoplasms 621Colorectal Neoplasms 529Lung Neoplasms 486Neoplasm Metastasis 434Multiple Myeloma 395Leukemia, Myeloid, Acute 391Ovarian Neoplasms 334Pancreatic Neoplasms 316Melanoma 297Squamous Cell Carcinoma of Head and Neck 268Recurrence 256Carcinoma, Hepatocellular 250Glioblastoma 238Brain Neoplasms 237Triple Negative Breast Neoplasms 213Carcinoma, Renal Cell 209Head and Neck Neoplasms 208Precursor Cell Lymphoblastic Leukemia-Lymphoma 201Lymphoma 201Stomach Neoplasms 197Endometrial Neoplasms 189Uterine Cervical Neoplasms 185Lymphoma, Non-Hodgkin 180Glioma 180Sarcoma 179Lymphoma, Large B-Cell, Diffuse 167Hematologic Neoplasms 162

Interventions

Miransertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Proteus Syndrome × 90 days × Clear all
NCT04316546 2026-06-04

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
38 enrolled

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡